INS and COVID-19: Although specific therapeutic measures for endocrine management were only infrequently needed in patients with COVID-19, background treatment dose adjustment was common: in 56.6% of centers, patients with type 1 diabetes needed insulin adjustments and in 26.9% of centers, patients with type 2 diabetes added insulin or adjusted oral medications.